M-mode echocardiography has been demonstrated to be a sensitive indicator of the sequential changes occurring in the heart in systemic arterial hypertension. The changes in function as well as anatomic features have been recorded. Previous analysis has focused on the anatomy and systolic function of the left ventricle, analysed in hypertensive heart disease. 13 normal subjects(Group I), 14 hypertensive patients without evidence of cardiac involvement(Group II) and 13 hypertensive patients with echocardiographic evidence of left ventricular hypertrophy(Group III) were compared using M-mode echocardiographic data and clinical. findings. The results are as follows : 1) Mean age are; Group I : 41 years(19-62), Group II : 49 years(25-67) and Group III : 53 years(30-83). There are no significant age difference between Group I and II. Sex ratio are 4:9, 8:6 and 7:6 respectively. 2) Mean arterial pressure are; Group I : 98+/-5mmHg, Group II : 126+/-7 mmHg and Group III : 131+/-101mmHg. 3) Left ventricular posterior wall thickness are; Group I : 0.87+/-0.12cm, Group II : 0.89+/-0.12cm and Group III : 1.32+/-0.18cm(p>0.05 in I vs II). 4) Left atrial dimension are; Group I : 2.77+/-0.68cm, Group II : 2.96+/-0.44cm and Group III: 3.12+/-0.60cm. 5) Left ventricular mass arel Group I : 194+/-51gm, Group II : 192+/-51gm and Group III : 318+/-77gm(p>0.05 in I vs II, p<0.001 in I vs II and II vs III). 6) Ejection fraction are; Group I : 0.57+/-0.09, Group II : 0.60+/-0.01 and Group III : 0.52+/-0.01)p>0.05). 7) Mitral valve EF solpe are; Group I : 113.70+/-23.26mm/sec, Group II : 81.14+/-17.22mm/sec and Group III : 69.92+/-22.70mm/sec(p<0.05 in I vs II, p<0.001 in I vs III and II vs III). 8) AEI are; Group I : 0.70+/-0.04, Group II : 0.56+/-0.07 and Group III: 0.48+/-0.07)p<0.001 in I vs II, I vs III and II vs III). From the above results, the atrial emptying index seems to be an early indicator of abnormalities of left ventricular diastolic compliance in hypertensive patients.
Arterial Pressure ; Compliance ; Echocardiography* ; Heart ; Heart Diseases ; Heart Ventricles ; Humans ; Hypertension ; Mitral Valve ; Sex Ratio

No abstract available.
Arthroplasty* ; Knee*

No abstract available.
Congenital Abnormalities* ; Osteotomy* ; Recurrence*

No abstract available.
Cesarean Section* ; Female ; Pregnancy

No abstract available.
Embryo Transfer* ; Embryonic Structures* ; Fertilization in Vitro* ; Pregnancy*

No abstract available.
Dental Porcelain* ; Fatigue* ; Fractures, Stress*

No abstract available.
Female ; Follicle Stimulating Hormone* ; Gonadotropin-Releasing Hormone* ; Gonadotropins* ; Humans ; Ovarian Diseases*

No abstract available.

No abstract available.
Female ; Methotrexate* ; Pregnancy ; Pregnancy, Tubal*

PURPOSE: We compared the first postoperative diagnostic and post-therapy scans of patients who received therapeutic doses of I-131, to investigate the difference in clinical outcomes between patients with concordant findings of diagnostic and post-therapy scans and patients with discrepant (more lesions in post-therapy scan) findings. MATERIALS AND METHODS: The first postoperative diagnostic and post-therapy radioiodine scans of one hundred forty three patients with well differentiated thyroid carcinoma were reviewed. Diagnostic scans were obtained following ingestion of 185 MBq of I-131 and post-therapy scans were obtained after therapeutic dose of 3.7~9.3 GBq of I-131. Successful ablation was defined as no radioiodine uptake on diagnostic radioiodine scan and normal range of serum thyroglobulin level (<10 ng/ml) during serum TSH elevation. RESULTS: Discrepant scan findings were noted in 25 (17.5%) patients. Twenty-two patients (15.4%) showed more lesions in post-therapy scan and 3 patients (2.1%) showed stunning effect. Nine (64.3%) of 14 patients with distant metastasis revealed metastatic lesion(s) only on post-therapy scan. Stunning effect was considered as sublethal damage in 1 patient and treatment by a diagnostic dose in 2 patients. Ablation was achieved in 52.4% (75/143) of all patients. Ablation rate and mean cumulative radioiodine dose were not different statistically between concordant and discrepant groups. CONCLUSION: There were 17.5% difference between diagnostic and post-therapy scan findings when using 185 MBq of I-131 as a diagnostic dose. However, 64.3% of distant metastases were revealed only on post-therapy scan. Ablation rate and mean cumulative radioiodine dose were not different statistically between concordant and discrepant groups. The stunning effect was considered as not only sublethal damage but also treatment by a small diagnostic dose of radioiodine.
Eating ; Humans ; Neoplasm Metastasis ; Reference Values ; Thyroglobulin ; Thyroid Gland* ; Thyroid Neoplasms*